13 results about "Immunosuppressive treatment" patented technology

The art does not provide systematic and reproducible methods to personalize dosing of multiple immunosuppressive medications after transplantation. This invention provides a method to systematize multi-drug immuno suppression management in tissue and organ transplantation using an artificial intelligence-based complex systems approach. In embodiments of this invention, immunosuppression drug dose, blood drug concentrations, donor-derived fraction of cell free DNA (dd-cfDNA %), and aspartate aminotransferase are used to indicate allograft status or a proxy for allograft status, to generate a phenotypic response surface to produce individual treatment modalities and dosages using empirically determined unique coefficients. This surface is used to calculate appropriate immunosuppression drug doses associated with the desired outcome for that patient. Embodiments of this disclosure are directed to identifying optimized combinations of inputs for the complex system of the immunosuppressed transplant patient in order to avoid transplant rejection while avoiding unnecessary toxicity and maintaining a robust enough immune response to fight infection.

To provide a method for identifying a therapy recommendation for a subject exhibiting dysregulated host response.SOLUTION: A classification of the subject of subtype A, subtype B, or subtype C is obtained. The therapy recommendation for the subject is identified based at least in part on the classification. Responsive to the classification of the subject comprising the subtype A, the therapy recommendation can be no immunosuppressive therapy. Responsive to the classification of the subject comprising the subtype B, the therapy recommendation can be no therapy recommendation, immune stimulation therapy, suppression of immune regulation therapy, blocking of immune suppression therapy, blocking of complement activity therapy, and / or anti-inflammatory therapy. Responsive to the classification of the subject comprising the subtype C, the therapy recommendation can be no therapy recommendation, immune stimulation therapy, suppression of immune regulation therapy, blocking of immune suppression therapy, modulators of coagulation therapy, and / or modulators of vascular permeability therapy.SELECTED DRAWING: Figure 1A

This invention discloses a myocarditis treatment prediction system integrating Transformer and causal reinforcement learning, comprising a data preprocessing module, a temporal encoding module, a causal decision-making module, and an interpretation regularization module. The data preprocessing module transforms multimodal clinical data into equally spaced state representation sequences; the temporal encoding module extracts global temporal dependencies through the multi-head self-attention mechanism of a Transformer encoder, outputting an abstract state vector; the causal decision-making module uses the abstract state vector as input to construct a Markov decision process, employs offline strategies to evaluate and estimate the expected clinical benefits of different intervention timings, and outputs individualized intervention recommendations and confidence levels through policy gradient optimization. This invention can capture the dynamic evolution of myocarditis disease under limited case conditions, assess the causal effects of different intervention strategies without real clinical trials, and provides a transparent and interpretable decision-making process, effectively assisting clinicians in identifying the optimal timing for immunosuppressive therapy.

The present invention provides inhibitors of cell-expressed TDO2 and pharmaceutical compositions thereof, which can be used to modulate the activity of tryptophan 2,3-dioxygenase; treat immunosuppression; treat medical conditions that benefit from inhibition of tryptophan degradation; enhance the effectiveness of anti-cancer treatment including administration of anti-cancer agents; and treat tumor-specific immunosuppression associated with cancer.

Allogeneic kidney transplantation is a common transplant procedure and an optimal form of therapy for individuals who reach end-stage renal disease, significantly improving their quality of life, as compared to dialysis and supportive care. Nonetheless, its success relies on lifelong immunosuppression (IS), which causes serious complications. Moreover, despite immunosuppression (IS), around 8% of renal transplants will be rejected due to T cell-mediated and / or antibody-mediated reactions towards donor-specific allo-antigens. Importantly, scarce kidney recipients achieve an immunosuppressive drug-free tolerance, suggesting the existence of active tolerance mechanisms. Biomarkers to predict rejection risks and identify patients in which tolerance mechanisms could allow IS weaning, as well as a non-invasive biomarker to diagnose a rejection event, are highly needed to improve patient's care. The inventors identify circulating CD73+ DP8α Tregs or the expansion of CD73+ DP8α Tregs after transplantation as a non-invasive biomarker to predict rejection risks from 3 months post-transplantation. These data advocate for the potential value of these cells to improve kidney grafted patients' care through IS minimization and / or tolerance-inducing therapies. Strikingly, these results were observed in two independent cohorts, at 1-year post-transplantation. The present invention relates to a method of determining in a subject whether a subject has or is at a risk of developing transplant rejection comprising the steps of: i) determining the frequency of CD73-expressing DP8α Tregs among any T cell subset in particular among total CD3+ T cells or among total CD4+ T cells or among total CD8+ T cells in a sample obtained from the subject after transplantation, ii) comparing the frequencies determined at step i) with a predetermined reference value wherein detecting differential between the frequency of CD73- expressing DP8α Tregs among any T cell subset in particular among total CD3+ T cells or among total CD4+ T cells or among total CD8+ T cells determined at step i) and the predetermined reference value is indicative of whether a subject has or is at a risk of developing a transplant rejection.

Compositions, methods, kits, systems, and software are provided for detecting over-immunosuppression or under-immunosuppression in a renal transplant recipient undergoing treatment with immunosuppressive therapy. In particular, the methods utilize a urine-based metabolite signature that differentiates over-immunosuppressed or under-immunosuppressed renal transplant recipients from those with a stable graft with high accuracy. In some embodiments, nuclear magnetic resonance spectroscopy and / or liquid chromatography-mass spectrometry techniques are used to detect metabolite features that differentiate patients who are over-immunosuppressed or under-immunosuppressed from those with stable grafts. The subject methods can be used for monitoring a renal transplant recipient to avoid over-immunosuppression, which can lead to infections that cause graft dysfunction or loss or even death, as well as monitoring a renal transplant recipient to avoid under-immunosuppression, which can lead to graft dysfunction, subclinical graft rejection, or rejection.

An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.

Presently provided are inhibitors of cellularly expressed TD02 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.

This specification provides methods and uses of treatment involving the administration of voclosporine to subjects who have previously received a calcineurin inhibitor (CNI), such as cyclosporine, tacrolimus, or derivatives thereof, for immunosuppression. In some embodiments, the methods and uses relate to selecting subjects who have previously received a CNI, such as cyclosporine, tacrolimus, or derivatives thereof, for immunosuppression, for the administration of voclosporine. In some embodiments, the methods and uses relate to treating or mitigating adverse effects that may be associated with immunosuppression using a CNI, such as cyclosporine, tacrolimus, or derivatives thereof. In some embodiments, the methods and uses include administering a therapeutically effective dose of voclosporine to the selected subjects.

The present invention relates to methods for monitoring potential indications of allogeneic organ rejection by monitoring transplanted hair follicles from the same donor of a transplanted organ, and for performing or modifying immunosuppressive therapy to ameliorate or prevent the occurrence of acute or chronic organ rejection. The methods of the invention may also be used to select candidate allogeneic solid organ donors for recipients, as well as to improve the occurrence of acute rejection of transplanted allogeneic solid organs, such as kidneys.

The invention belongs to the technical field of biological medicine, and particularly relates to application of EEF1B2 serving as a drug target or EEF1B2 in preparation of anti-tumor immunosuppression drugs. By inhibiting the EEF1B2, the generation and differentiation of MDSCs in colorectal adenoma are remarkably reduced, and the immunosuppression function of MDSCs is interfered, so that the growth or disease course development of colorectal adenoma is remarkably slowed down or reduced. The invention provides a medicine CBD containing an EEF1B2 inhibitor, particularly innovative application of the CBD as the EEF1B2 inhibitor, and a method for treating colon adenoma and preventing further canceration of the adenoma by inhibiting the EEF1B2 function. The invention further relates to a method for detecting the regulatory relation between the EEF1B2 and the CEBP beta. The implementation of the invention provides a new strategy and a drug development direction for treatment of colon adenoma and intervention of further development of colon adenoma into immunosuppressive treatment of colorectal cancer.

The present invention relates to a pharmaceutical composition for treating non-alcoholic fatty liver or non-alcoholic steatohepatitis, the pharmaceutical composition comprising an anti-ICAM-1 antibody as an active ingredient. The present invention takes into account that non-alcoholic steatohepatitis can be treated by regulating inflammatory responses through ICAM-1 targeting in liver tissue, and is based on the discovery that using the anti-ICAM-1 antibody in immunosuppressive therapy following a liver transplant effectively suppresses inflammatory response in hepatocytes and stably maintains liver function, and the expression of genes associated with the mechanism of non-alcoholic steatohepatitis is effectively regulated in inflamed liver tissue through administration of the anti-ICAM-1 antibody. Through this, the anti-ICAM-1 antibody according to the present invention is expected to be effectively used for treating non-alcoholic fatty liver or non-alcoholic steatohepatitis.

The invention discloses a fluorescent quantitative detection kit for positioning a transplanted heart injury tissue source. The fluorescent quantitative detection kit specifically comprises the following steps: S1, collecting and treating a serum sample; s2, carrying out RNA kit extraction by adopting serum or plasma; s3, gDNA removal and reverse transcription are carried out; s4, carrying out quantitative PCR (Polymerase Chain Reaction) detection by adopting an SYBR Green method; and S5, data analysis. The invention relates to the technical field of medical diagnosis. According to the fluorescent quantitative detection kit for positioning the injured tissue source of the transplanted heart, accurate positioning of the injured tissue source of the heart is realized through multi-index joint detection, an important basis is provided for clinical individualized immunosuppression treatment, and the occurrence rate and the death rate of complications after heart transplantation are remarkably reduced; the kit can be used for accurately detecting the marker derived from the damaged heart tissue.